STOCK TITAN
  1. Home
  2. News
  3. ADAP

Adaptimmune Therapeutics plc American Depositary Shares - $ADAP STOCK NEWS

Welcome to our dedicated page for Adaptimmune Therapeutics plc American Depositary Shares news (Ticker: $ADAP), a resource for investors and traders seeking the latest updates and insights on Adaptimmune Therapeutics plc American Depositary Shares stock.

Our selection of high-quality news articles is accompanied by an expert summary from Rhea-AI, detailing the impact and sentiment surrounding the news at the time of release, providing a deeper understanding of how each news could potentially affect Adaptimmune Therapeutics plc American Depositary Shares's stock performance. The page also features a concise end-of-day stock performance summary, highlighting the actual market reaction to each news event. The list of tags makes it easy to classify and navigate through different types of news, whether you're interested in earnings reports, stock offerings, stock splits, clinical trials, fda approvals, dividends or buybacks.

Designed with both novice traders and seasoned investors in mind, our page aims to simplify the complex world of stock market news. By combining real-time updates, Rhea-AI's analytical insights, and historical stock performance data, we provide a holistic view of Adaptimmune Therapeutics plc American Depositary Shares's position in the market.

News
Adaptimmune Reports Third Quarter Financial Results and Business Update
Rhea-AI Summary
Adaptimmune Therapeutics plc (NASDAQ: ADAP): Afami-cel's BLA submission on track for Q4 completion, showing superior survival rates for synovial sarcoma patients. SURPASS Phase 1 trial reports 75% response rate in ovarian, urothelial, and head & neck cancers. Pipeline update includes termination of Gavo-cel and TC-510 programs. Financially, the company's cash runway is confirmed into early 2026.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-5.54%
Tags
earnings
-
News
Adaptimmune Selects ADP-600 as Clinical Candidate for Best-in Class PRAME Strategy
Rhea-AI Summary
Adaptimmune Therapeutics plc (NASDAQ: ADAP) provides progress update on PRAME program (ADP-600), announcing 10x higher sensitivity to target peptide than competitors, entry into the clinic in 2024, and selection of next-gen approaches.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-5.54%
Tags
none
-
News
Adaptimmune Reports Better Outcomes for People with Synovial Sarcoma who Received Afami-cel Compared to Historical Control
Rhea-AI Summary
Adaptimmune Therapeutics plc is set to present outcome data from Cohort 1 of its pivotal SPEARHEAD-1 trial at the Connective Tissue Oncology Society (CTOS) annual meeting. The data shows that approximately 39% of patients who received afami-cel had clinical responses, with a median duration of response of around 12 months. The median overall survival in the trial was approximately 17 months, compared to a historical median overall survival of less than 12 months for patients with synovial sarcoma who had received two or more prior lines of therapy. Additionally, 70% of patients who responded to afami-cel were alive two years post-treatment.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-2.52%
Tags
none
News
Adaptimmune Reports Positive Data with Lete-cel[1] from an Interim Analysis of the Pivotal IGNYTE-ESO Trial for People with Synovial Sarcoma or MRCLS
Rhea-AI Summary
Adaptimmune Therapeutics plc (NASDAQ: ADAP) reports positive interim analysis results from the IGNYTE-ESO trial with lete-cel for synovial sarcoma and MRCLS. 40% of patients had clinical responses, with a median duration of response of approximately 11 months. A small substudy showed an 80% response rate in treatment-naïve patients. Safety findings were consistent with previous data.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-2.52%
Tags
none
-
News
Adaptimmune to Report Q3 2023 Financial and Business Updates on Wednesday, November 8, 2023
Rhea-AI Summary
Adaptimmune Therapeutics to report Q3 financial results and provide business updates on November 8, 2023.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-2.94%
Tags
conferences earnings
-
News
Next-Generation TCR T-cell Therapy (ADP-A2M4CD8) Demonstrates Strong Efficacy in a Broad Range of Solid Tumors; Adaptimmune Presents Data Update from its SURPASS trial at ESMO
Rhea-AI Summary
Adaptimmune presents positive clinical data on ADP-A2M4CD8 therapy for solid tumors at ESMO Congress
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
6.19%
Tags
none
News
Dr. Karen Chagin Joins Adaptimmune as Senior Vice President of Early-Stage Development
Rhea-AI Summary
Adaptimmune Therapeutics announces appointment of Karen Chagin as Senior VP of Early-Stage Development
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
8.84%
Tags
none
-
News
Adaptimmune Reports Second Quarter Financial Results and Business Update
Rhea-AI Summary
Adaptimmune Therapeutics reported progress on the afami-cel BLA, with the submission targeted for Q4 2023. They also provided updates on the transition of lete-cel from GSK and the initiation of the Phase 2 SURPASS-3 trial in ovarian cancer. The company completed a strategic combination with TCR2, adding pipeline assets and increasing total liquidity. Pipeline data readouts are expected over the next 18 months, and the cash runway extends into early 2026.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-1.16%
Tags
earnings
-
News
Adaptimmune to Report Q2 2023 Financial and Business Updates on Wednesday, August 9, 2023
Rhea-AI Summary
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-0.11%
Tags
conferences earnings
News
Adaptimmune Announces Completion of Strategic Combination with TCR2 Therapeutics Creating a Preeminent Solid Tumor Cell Therapy Company
Rhea-AI Summary
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
6.86%
Tags
none
Stock ADAP logo
Adaptimmune Therapeutics plc American Depositary Shares

Nasdaq:ADAP

ADAP Rankings

#3415 Ranked by Market Cap
#4938 Ranked by Stock Gains
N/A Ranked by Dividends

ADAP Stock Data

304.12M
734.09M
0.2%
67.52%
1.3%
Biological Product (except Diagnostic) Manufacturing
Manufacturing
Link
United States of America
ABINGDON, OXFORDSHIRE

About ADAP

adaptimmune llc is a multinational, clinical-stage biopharmaceutical company focused on developing novel immunotherapies using its proprietary t-cell receptor platform that has the potential to transform the treatment of cancer. established in 2008, the company has grown from being privately held to one of the most successful biopharmaceutical initial public offerings (ipo) in 2015. with u.s. operations based in philadelphia, pa, adaptimmune is a company founded on strong science that has led to a robust pipeline of immuno-oncology product candidates, a growing research & development platform and ongoing plans for expansion. for more information about adaptimmune, please visit www.adaptimmune.com. if interested in joining our fast growing team, click on the careers tab of this page.